Publications by authors named "N Shrotri"

The dorsal cornu ammonis 2 (dCA2) region of the hippocampus enables the discrimination of novel from familiar conspecifics. However, the neural bases for more complex social-spatial episodic memories are unknown. Here we report that the spatial and social contents of an aversive social experience require distinct hippocampal regions.

View Article and Find Full Text PDF

Introduction: International medical graduates (IMGs) account for 41% of the UK doctor's workforce but often work in isolated roles, receive minimal constructive feedback regarding their work and offered limited opportunities for career progression. We conducted a survey researching the views of IMGs or doctors from ethnic minority backgrounds on the support given to them.

Methods: A survey was carried out on physician demographics, grade and date of first NHS appointment, familiarity and support offered in NHS, induction and study leave, Professional and Linguistic Assessments Board exams and General Medical Council (GMC) referrals.

View Article and Find Full Text PDF

The ability to distinguish a threatening from non-threatening conspecific based on past experience is critical for adaptive social behaviors. Although recent progress has been made in identifying the neural circuits that contribute to different types of positive and negative social interactions, the neural mechanisms that enable the discrimination of individuals based on past aversive experiences remain unknown. Here, we developed a modified social fear conditioning paradigm that induced in both sexes robust behavioral discrimination of a conspecific associated with a footshock (CS+) from a non-reinforced interaction partner (CS-).

View Article and Find Full Text PDF
Article Synopsis
  • The GOLIATH study is a 2-year clinical trial comparing two treatments for benign prostatic obstruction: transurethral resection of the prostate (TURP) and photoselective vaporization using the GreenLight XPS laser, with a focus on maintaining treatment effects seen at the 6-month mark over two years.
  • The trial involved 281 patients across 29 centers in Europe and measured outcomes like the International Prostate Symptom Score and other health indicators, aiming to prove that GL-XPS is not inferior to TURP.
  • Results showed that GL-XPS maintained similar effectiveness and safety compared to TURP over the two years, with fewer complications and comparable reductions in prostate size and specific antigen levels, though some
View Article and Find Full Text PDF